...
首页> 外文期刊>Journal of Medicinal Chemistry >Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
【24h】

Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands

机译:雄激素受体配体和细胞凋亡蛋白配体抑制剂蛋白降解腺体受体蛋白质降解诱导剂

获取原文
获取原文并翻译 | 示例

摘要

Targeted protein degradation using small molecules is a novel strategy for drug development. We have developed hybrid molecules named specific and nongenetic inhibitor of apoptosis protein [IAP]-dependent protein erasers (SNIPERs) that recruit IAP ubiquitin ligases to degrade target proteins. Here, we show novel SNIPERs capable of inducing proteasomal degradation of the androgen receptor (AR). Through derivatization of the SNIPER(AR) molecule at the AR ligand and IAP ligand and linker, we developed 42a (SNIPER(AR)-51), which shows effective protein knockdown activity against AR. Consistent with the degradation of the AR protein, 42a inhibits AR-mediated gene expression and proliferation of androgen-dependent prostate cancer cells. In addition, 42a efficiently induces caspase activation and apoptosis in prostate cancer cells, which was not observed in the cells treated with AR antagonists. These results suggest that SNIPER(AR)s could be leads for an anticancer drug against prostate cancers that exhibit AR-dependent proliferation.
机译:使用小分子的靶向蛋白质降解是一种用于药物发育的新策略。我们已经开发出称为特异性和环境抑制剂的凋亡分子凋亡蛋白[IAP]依赖性蛋白擦除剂(狙击手),其募集IAP泛素连接酶降解靶蛋白。在这里,我们展示了能够诱导雄激素受体(Ar)的蛋白酶体降解的新型狙击手。通过在Ar配体和IAP配体和接头处的狙击衍生化分子和接头,我们开发了42A(狙击(Ar)-51),其显示对AR的有效蛋白质敲低活性。与Ar蛋白的降解一致,42A抑制Ar介导的基因表达和雄激素依赖性前列腺癌细胞的增殖。此外,42A有效地在用AR拮抗剂处理的细胞中观察到前列腺癌细胞中的胱天蛋白酶活化和细胞凋亡。这些结果表明,狙击(AR)S可以导致抗癌药物对抗前列腺癌,其表现出依赖性增殖。

著录项

  • 来源
    《Journal of Medicinal Chemistry 》 |2018年第2期| 共33页
  • 作者单位

    Divisions of Molecular Target and Gene Therapy Products National Institute of Health Sciences 1-18-1 Kamiyoga Setagaya-ku Tokyo 158-8501 Japan;

    Pharmaceutical Research Division Takeda Pharmaceutical Co. Ltd. 26-1 Muraoka-Higashi 2-chome Fujisawa Kanagawa 251-0012 Japan;

    Pharmaceutical Research Division Takeda Pharmaceutical Co. Ltd. 26-1 Muraoka-Higashi 2-chome Fujisawa Kanagawa 251-0012 Japan;

    Pharmaceutical Research Division Takeda Pharmaceutical Co. Ltd. 26-1 Muraoka-Higashi 2-chome Fujisawa Kanagawa 251-0012 Japan;

    Divisions of Molecular Target and Gene Therapy Products National Institute of Health Sciences 1-18-1 Kamiyoga Setagaya-ku Tokyo 158-8501 Japan;

    Divisions of Molecular Target and Gene Therapy Products National Institute of Health Sciences 1-18-1 Kamiyoga Setagaya-ku Tokyo 158-8501 Japan;

    Pharmaceutical Research Division Takeda Pharmaceutical Co. Ltd. 26-1 Muraoka-Higashi 2-chome Fujisawa Kanagawa 251-0012 Japan;

    Pharmaceutical Research Division Takeda Pharmaceutical Co. Ltd. 26-1 Muraoka-Higashi 2-chome Fujisawa Kanagawa 251-0012 Japan;

    Pharmaceutical Research Division Takeda Pharmaceutical Co. Ltd. 26-1 Muraoka-Higashi 2-chome Fujisawa Kanagawa 251-0012 Japan;

    Pharmaceutical Research Division Takeda Pharmaceutical Co. Ltd. 26-1 Muraoka-Higashi 2-chome Fujisawa Kanagawa 251-0012 Japan;

    Pharmaceutical Research Division Takeda Pharmaceutical Co. Ltd. 26-1 Muraoka-Higashi 2-chome Fujisawa Kanagawa 251-0012 Japan;

    Divisions of Molecular Target and Gene Therapy Products National Institute of Health Sciences 1-18-1 Kamiyoga Setagaya-ku Tokyo 158-8501 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号